Infiltrating lipoma

Summary

Infiltrating lipoma (MONDO:0004075) is a disease. A subtype of lipoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	infiltrating lipoma
Mondo ID	MONDO:0004075
DOID	DOID:7014
NCIT	C7450, C7451
UMLS	C0334473
MedGen	90788
Is cancer (heuristic)	no

Also known as: intramuscular lipoma · intramuscular lipoma (morphologic abnormality)

Disease family

This is a subtype of lipoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › musculoskeletal system disorder › musculoskeletal system benign neoplasm › benign connective and soft tissue neoplasm › benign lipomatous neoplasm › lipoma › infiltrating lipoma

Related subtypes (29): endobronchial lipoma, spindle cell lipoma, esophageal lipoma, skin lipoma, liver lipoma, pleomorphic lipoma, conventional lipoma, kidney lipoma, pleural lipoma, breast lipoma, chest wall lipoma, gallbladder lipoma, external ear lipoma, axillary lipoma, paratesticular lipoma, chondroid lipoma, thymus lipoma, heart lipoma, central nervous system lipoma, colorectal lipoma, internal auditory canal lipoma, tendon sheath lipoma, lumbosacral lipoma, angiolipoma, familial multiple lipomatosis, hibernoma, lipoma of stomach, lipoma of face, tonsillar lipoma

Subtypes (1): infiltrating angiolipoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.